FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors

Trial

TRIDENT-1

Drug

AUGTYRO (repotrectinib) · ROS1 inhibitor

Condition

Other solid neoplasm